A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1035 participants.

Also called NCT07282600

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,035 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07282600
  • EU CT 2025-523658-15-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, China, Czechia, Germany, India, Japan, Mexico, Poland, Puerto Rico, Slovakia, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07282600. Randomized; double masking; primary purpose treatment. Start 2025-12-15 (actual); primary completion 2028-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Acronym
ENLIGHTEN-2
Condition
Overweight
Condition
Obesity
Intervention (Drug)
Eloralintide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07282600
Content hash
9fa1ac5f785c866f6d9ca200b5eae9c8f9d8f1485066494ac072b9e13644ca00